Embody
Embody developed collagen-based regenerative matrices for soft tissue repair using advanced biofabrication.
- CEO / Founder
- Jeff Conroy
- Team Size
- 50-100
- Stage
- Acquired
- Total Funding
- $44.2M
- Latest Round
- Acquired
- Key Investors
- Zimmer Biomet (acquirer), DARPA, Horizon Technology Finance, Genesis Innovation Group/cultivate(MD), 757 Angels, Black Forest Ventures
Technology & Products
Key Products
Collagen repair matrices, Regenerative tissue products
Technological Advantage
Developed under DARPA Atoms 2 Products program; molecular-scale assembly for superior strength
Differentiation
Value Proposition
High-strength biocompatible collagen repair materials with tailorable 3D structures.
How They Differentiate
Molecular-level assembly creating superior collagen structures; DARPA-validated technology
Market & Competition
Target Customers
Orthopedic surgeons, sports medicine specialists, hospitals
Industry Verticals
Orthopedics, Sports Medicine, Regenerative Medicine
Competitors
Smith & Nephew, Arthrex, Stryker
Growth & Milestones
Growth Metrics
$44.2M total funding raised; $14.35M DARPA non-dilutive funding; Acquired by Zimmer Biomet January 2023 for $155M
Major Milestones
2014: Founded in Norfolk, VA by Jeff Conroy and Michael Francis; 2018: $3.6M seed round; DARPA Atoms 2 Products funding ($14.35M total); Developed Tapestry biointegrative implant, Microbraid collagen suture, Microbrace; 2021: $20.5M funding round; 2022-09: $10.4M Series C; 2023-01-05: Acquired by Zimmer Biomet for $155M
Notable Customers
Orthopedic surgeons, Sports medicine practitioners, Medical centers using Tapestry implant and Microbrace products